Identification of markers of blood hypercoagulation and exacerbated inflammation in obese patients with COVID-19 in the Federal District

Obesity is one of the biggest risk factors for worsening COVID-19. However, it is not yet known exactly why and how this occurs. Our research aims to identify why people with obesity have a higher mortality rate due to COVID-19. Our initial results of our research already show us that obese people have a dysfunction in the blood clotting system, making them more likely to form blood clots and thrombi, which are related to severe COVID-19 and are also a cause high death rates in patients with COVID-19. In addition, the adipose tissue of obese patients is an extremely inflamed tissue, with high production of cytokines and inflammatory mediators, which are also related to a severe condition of the disease, and with high death rates from COVID-19. Our proposal is also that the adipose tissue shows expression of the SARS-CoV-2 virus input receptor, ACE-2, and in this way the adipose tissue functions as a reservoir for viral replication. We also point out that the early use of anticoagulants such as heparin and specific anti-inflammatory drugs must be of special importance in obese patients with COVID-19, which can significantly decrease mortality rates in people with obesity affected by COVID-19. We recently published a scientific article that provides valuable analysis and reflections for a better understanding of how obesity is related to the increased risk of death from COVID-19 ( and in this way the adipose tissue acts as a reservoir for viral replication. We also point out that the early use of anticoagulants such as heparin and specific anti-inflammatory drugs must be of special importance in obese patients with COVID-19, which can significantly decrease mortality rates in people with obesity affected by COVID-19. We recently published a scientific article that provides valuable analysis and reflections for a better understanding of how obesity is related to the increased risk of death from COVID-19 ( and in this way the adipose tissue acts as a reservoir for viral replication. We also point out that the early use of anticoagulants such as heparin and specific anti-inflammatory drugs must be of special importance in obese patients with COVID-19, which can significantly decrease mortality rates in people with obesity affected by COVID-19. We recently published a scientific article that provides valuable analysis and reflections for a better understanding of how obesity is related to the increased risk of death from COVID-19 ( being able to significantly reduce the mortality rates in people with obesity affected by COVID-19. We recently published a scientific article that provides valuable analysis and reflections for a better understanding of how obesity is related to the increased risk of death from COVID-19 ( being able to significantly reduce the mortality rates in people with obesity affected by COVID-19. We recently published a scientific article that provides valuable analysis and reflections for a better understanding of how obesity is related to the increased risk of death from COVID-19 (https://www.frontiersin.org/articles/10.3389/fendo.2020.00530/abstract).Thus, our project aims to identify markers of blood hypercoagulation and exacerbated inflammation in obese patients with COVID-19 in the Federal District, as well as to verify possible effectiveness of the use of specific anticoagulants and anti-inflammatory drugs in the treatment of obese patients with COVID-19. For this, patients with a body mass index greater than 34 positive for COVID-19 by RT-PCR test and admitted to the hospitals participating in the research, will have blood samples collected and analyzes of the presence of different blood clotting markers will be made and also inflammation markers. The efficiency of treatment with anticoagulants, such as heparin, and anti-inflammatory in these patients will also be evaluated when they have been treated with these drugs. It is hoped that the identification of levels of markers of blood hypercoagulation and exacerbated inflammation in obese patients with COVID-19 in DF will promote a more personalized, targeted and more successful therapy for these individuals. It is hoped that the early identification of which are the most prevalent markers of blood hypercoagulation and exacerbated inflammation in obese patients with COVID-19 in DF, may allow the introduction of more effective therapy in these cases, such as the targeted use of certain anticoagulants and specific anti-inflammatory drugs, which can lead to a considerable decrease in the worsening of these obese patients by COVID-19, and consequently a decrease in the death rates of these patients.